03 August 2018
Visiongain has launched a new pharma report Botanical and Plant-Derived Drugs Market Forecast to 2027: Prospects for Leading Companies in Steroids, Phenols, Terpenes, Glycosides and Others, Sativex, Marinol Nabilone, Dexanabinol, CT-3, Cannabinor, HU 308, HU 331, Rimonabant, Taranabant
Plant derived substances have recently become of great interest owing to their versatile applications. Medicinal plants have been used for centuries as remedies for human diseases and offer a new source of biologically active chemical compound as antimicrobial agent. Medicinal plants are the richest bio-resources of drugs of traditional medicinal systems, modern medicines, nutraceuticals, food supplements, folk medicines, pharmaceuticals, intermediate and chemical entitled for synthetic drugs. It has been estimated that 14 - 28% of higher plant species are used medicinally and that 74% of pharmacologically active plant derived components were discovered after following up on ethno medicinal use of the plants. Botanical drugs are those drugs which are derived from medicinal plants. Plant derived drugs are combination of botanical as well as other approved drugs that contains plant materials, synthetic and semi synthetic substances.
The lead analyst of the report commented “There has been rising interest in botanical drugs, with many pharmaceutical companies investigating the commercial potential. The global botanical derived drugs market will experience steady growth over the forecast period.
Growth in the market is primarily driven by increasing focus on the development of drugs for new indications, increasing prevalence of various chronic diseases and public as well as private investment for botanical and plant derived drug. However, challenges in clinical trials and stringent laws and regulations for approval will deplete the market.”
Leading companies featured in the report include Abbott Laboratories, Bayer AG, Eli Lilly
Johnson & Johnson, Novartis AG, Pfizer, Inc., Bristol-Myers Squibb (BMS), Medigene AG
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.